Biogen (BIIB) Accumulated Expenses (2010 - 2012)

Biogen's Accumulated Expenses history runs 3 years deep, the most recent figure standing at $156.7 million for Q2 2012.

• In Q2 2012, Accumulated Expenses changed N/A year-over-year to $156.7 million; the TTM figure through Jun 2012 stood at $156.7 million (changed N/A YoY), while the FY2011 annual figure was $176.3 million, up 10.39% from the prior year.
• Accumulated Expenses for Q2 2012 stood at $156.7 million, up from $108.5 million in the prior quarter.
• The five-year high for Accumulated Expenses was $176.3 million in Q4 2011, with the low at $108.5 million in Q1 2012.
• The 3-year median for Accumulated Expenses is $158.2 million (2010), against an average of $150.3 million.
• Peak annual rise in Accumulated Expenses reached 10.39% in 2011, while the deepest fall reached 10.39% in 2011.
• Biogen's Accumulated Expenses stood at $159.7 million in 2010, then climbed by 10.39% to $176.3 million in 2011, then decreased by 11.12% to $156.7 million in 2012.
• Business Quant data shows BIIB's Accumulated Expenses at $156.7 million in Q2 2012, $108.5 million in Q1 2012, and $176.3 million in Q4 2011.